Clostridium difficile infection (CDI) is a common nosocomial infection. Lung cancer patients have a high risk of developing CDI because of continuous antibiotic treatment or chemotherapy, prolonged hospitalization, and general weakness. This study aimed to analyze predisposing or associated risk factors for CDI in lung cancer patients receiving chemotherapy. This study was a retrospective review of 188 lung cancer patients who were admitted to the Wonkwang University Hospital between 2008 and 2009. Of the 188 patients, 44 were diagnosed with CDI. The albumin levels were significantly lower and the performance status (PS) score was significantly higher in lung cancer patients with CDI than in those without CDI ( P º 0.05). In conclusion, clinicians should consider the possibility of CDI occurrence in lung cancer patients receiving chemotherapy, particularly in those with low albumin levels and high PS scores, because most lung cancer patients have a high risk of developing CDI.
INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality worldwide (1) . Despite its poor prognosis, an increasing number of lung cancer patients are being admitted to medical intensive care units (MICUs) because of critical illnesses related to either the underlying malignancy (regardless of the cancer stage) or comorbidities (2) . With an increase in the number of hospital admissions, the frequencies of prolonged admission, continuous antibiotic use, and general patient weakness have also increased, thereby placing lung cancer patients at a high risk of contracting nosocomial infections.
Clostridium difficile infection (CDI) is a common nosocomial infection associated with prior antibiotic use (3, 4) . Other identified risk factors for CDI include old age, underlying illness, prolonged hospitalization, and chemotherapy. Although most lung cancer patients receiving chemotherapy have a high risk of developing CDI (5) (6) (7) (8) , only few are diagnosed with CDI.
Therefore, we aimed to analyze predisposing or associated risk factors for CDI in lung cancer patients receiving chemotherapy.
MATERIALS AND METHODS
At the pulmonary department of the Wonkwang University Hospital, 223 patients were diagnosed with lung cancer by biopsy between January 2008 and December 2009. Of the 223 patients, 188 were admitted, and their outpatient records were included in the study. Of these 188 patients, 44 were diagnosed with CDI.
We obtained information regarding patient age, gender, history, lung cancer pathology, lung cancer stage, laboratory data (white blood cell [WBC] count, albumin level, and C-reactive protein [CRP] level), performance status (PS) score at lung cancer diagnosis, and chemotherapy type. Patient history included any incidence of cardiovascular disease, diabetes mellitus, chronic kidney disease, past or current need for hemodialysis (not including the ICU), pulmonary disease, hematologic malignancy, and solid tumor malignancy, except lung cancer and chronic liver disease. The tumor stage of patients with non-small cell lung cancer was recorded according to the tumor-node-metastasis classification system (9) and that of patients with smallcell lung cancer was recorded according to the limited disease/extensive disease classification system (10) . The medication data (antibiotics and chemotherapy) were limited to 8 weeks before the onset of each patient's abdominal symptoms. Stage I-IIIA patients not receiving adjuvant chemotherapy after operation were not included in the study. In addition, patients with abdominal symptoms at the time of lung cancer diagnosis or previous CDI were not included in the study.
CDI diagnosis is based on a combination of clinical and laboratory findings (11) . A case definition for typical CDI presentation includes the following findings: (i) the presence of diarrhea, defined as passage of AE3 unformed stools in Ã24 consecutive hours and abdominal pain or bloating; (ii) a positive stool test result for the presence of toxigenic C. difficile or its toxins or colonoscopic or histopathologic findings demonstrating pseudomembranous colitis. The types of antibiotics administered and period of their use were noted before the Qualitative data were expressed as numbers (percentages) and quantitative data as medians (ranges). The chi-square test was used to compare the distribution of patient characteristics, and an independent t-test was used to analyze continuous variables. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) software, version 15 (SPSS Inc., Chicago, Ill., USA) (a P value º0.05 was considered statistically significant).
RESULTS
Patient demographics: This study included 188 lung cancer patients. Of these, 44 were diagnosed with CDI. We compared clinical data between lung cancer patients with CDI (CDI (＋)) and those without CDI (CDI (-)). The median ages of CDI (＋) and CDI (-) patients were 69.2 ± 9.4 years and 69.8 ± 10.2 years, respectively. The baseline characteristics were similar between the 2 study groups, except for the PS score and albumin level. At lung cancer diagnosis, the PS score was higher in CDI (＋) patients than in CDI (-) patients. PS scores significantly differed between CDI (＋) and CDI (-) patients ( P º 0.05 and P º 0.05, respectively, for trend). The results of the laboratory examination performed at lung cancer diagnosis showed significantly lower levels of albumin in CDI (＋) patients than in CDI (-) patients (P º 0.05). In contrast, the WBC count and CRP levels did not differ significantly between the 2 groups. Length of hospital stay of À14 days, duration of antibiotic use, and types of antibiotics used did not differ significantly between the 2 groups (Table 1) .
Correlation between CDI and antibiotic use in CDI (＋) patients: Because antibiotics are a well-known risk factor for CDI, we investigated the type of antibiotics that were administered to the patients. For various reasons such as pneumonia, sepsis, and unknown fever, the majority of lung cancer patients were treated with antibiotics, of which, cephalosporin was the most commonly administered. Of all the CDI (＋) patients, 40 (91z) were treated with antibiotics (cephalosporin, 30; quinolone, 7; and macrolide, 3), and the average duration of antibiotic use was 17.4 ± 23.6 days ( Table 2) .
Clinical characteristics of CDI (＋) patients: CDI symptoms were observed after an average period of 18.4 ± 24.6 days of antibiotic use. The most common symptoms were diarrhea (36 patients, 82z) and abdominal pain (24 patients, 55z), and some patients complained of fever, vomiting, and general weakness ( Table 2) . Most CDI (＋) patients with abdominal pain experienced diarrhea; however, 6 patients complained of abdominal pain without diarrhea. Among these 6 patients, 5 did not show any other symptoms such as fever and vomiting.
In our study, CDI was diagnosed using a C. difficile toxin assay and by endoscopic examination. Of the 44 patients who underwent the C. difficile toxin assay, only 1 showed a negative result. However, because of the persistence of symptoms such as diarrhea and abdominal pain, endoscopic examination was performed for this patient.
Treatment and treatment response: Initially, the CDI (＋) patients were treated with metronidazole (39 patients, 89z) or vancomycin (4 patients, 9z). Of these patients, 5 died because of severe sepsis, without pneumonia or cardiac arrest.
Approximately 90z of the CDI (＋) patients were clinically cured; however, within 1 month after symptom improvement, 9 patients experienced a relapse (Table 3) .
DISCUSSION
The main objective of this study was to identify clinical risk factors associated with lung cancer that are correlated with CDI. Several risk factors for CDI have been previously reported. The most important modifiable risk factor for CDI is antibiotic administration (3, 4) . Both longer exposure to antimicrobials, as opposed to shorter exposure, and exposure to multiple antimicrobials, as opposed to exposure to a single agent, increase the risk for CDI (12) . Cancer chemotherapy is another risk factor for CDI that is, at least in part, mediated by the antimicrobial activity of several chemotherapeutic agents but could also be related to the immunosuppressive effects of neutropenia (5) (6) (7) (8) . The effect of chemotherapy on the minimum concentration of C. difficile required for colitis development and how chemotherapeutic agents modulate the risk of broadspectrum antibiotics promoting CDI development are uncertain factors that may unequally affect certain cancer patients more than others (13) . Other identified risk factors for CDI include old age, severity of underlying illness, enteral tube feeding, and treatment with antacids such as H2-blockers and proton-pump inhibitors (14) (15) (16) (17) . Our findings have aided the identification of risk factors for CDI in lung cancer patients receiving chemotherapy. Because most patients in our study were À65 years old and were treated with continuous chemotherapy and antibiotics after lung cancer diagnosis, a definitive cause of CDI could not be established. We found no difference in age, gender, history, lung cancer pathology, lung cancer stage, and length of hospital stay between CDI (＋) and CDI (-) patients. However, our results suggested that low albumin levels could be a significant risk factor for CDI. This finding is supported by a previous study, in which a serum albumin level of º2.5 g/dL on admission and a decrease in the serum albumin level of À1.1 g/dL at symptom onset were correlated with increased mortality in hospitalized patients of an older age who developed C. difficile-associated diseases (18) . Low albumin levels could indicate reduced total protein levels, including the levels of serum immunoglobulins that usually neutralize the C. difficile toxin (19) . Another significant factor was the PS score, which is an attempt to quantify the general well-being and activities of daily life of cancer patients (20) . The PS score is a simple and very useful tool in medical oncology and is used to determine whether a patient can receive chemotherapy and whether dose adjustment is necessary. A PS score of 3-4 indicates poor overall health and reportedly has an ad-verse impact on prognosis of patients with solid tumors admitted to the ICU (20) . Because patients with a PS score of 3-4 at lung cancer diagnosis are evidently critically ill as a result of the underlying disease (cancer), these patients could be exposed to many risk factors for CDI such as length of hospital stay and antibiotic use. The results of this study suggest that low albumin levels and a high PS score are potential risk factors for CDI in lung cancer patients. The diagnosis of CDI is not always simple and is based on a combination of clinical symptoms and laboratory findings (11, 21) . Diarrhea is the most common manifestation of CDI. Fever, cramping, abdominal discomfort, and peripheral leukocytosis are common; however, they occur in less than 50z of patients (22) . Complications of severe C. difficile colitis include dehydration, electrolyte disturbances, hypoalbuminemia, toxic megacolon, bowel perforation, hypotension, renal failure, systemic inflammatory response syndrome, sepsis, and death (23, 24) . If patients with CDI risk factors complain of diarrhea, CDI should be suspected. However, lung cancer patients may complain of abdominal pain because of various reasons such as cancer metastasis and chemotherapy-related complications. CDI diagnosis is difficult in patients who experience abdominal pain or abdominal bloating without diarrhea, therefore, in such patients, CDI diagnosis could be delayed. Rapid diagnosis and proper CDI management is important.
The present study has several limitations, including its retrospective nature. There is a possibility that selection bias influenced the significance of our findings. Our study is from a single institution and has a small sample size, which limits the extension of our findings to the general population. Further research including a larger sample size and prospective methodology, assessmentof additional risk factors for CDI in lung cancer patients, and determination of the role of albumin levels in CDI is required to confirm our findings.
In conclusion, most lung cancer patients receiving chemotherapy are exposed to multiple risk factors for CDI. In this study, lung cancer patients with low albumin levels and high PS scores had a high risk of developing CDI. Therefore, clinicians should consider the possibility of CDI occurrence in lung cancer patients receiving chemotherapy, particularly in those with low albumin levels and high PS scores.
